Alzheimer Europe continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in a least one European country. The service provides information on phase II and III clinical trials that are investigating drugs for the prevention and treatment of dementia and/or Alzheimer’s disease. In May 2020, two new trials have been added to the service:
-
The purpose of the T-817MA Phase II study is to evaluate the efficacy and safety of T-817MA (Edonerpic) in people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer's disease
-
The Phase III LUCIDITY study is to determine the safety and efficacy of TRx0237 (hydromethylthionine) in people with mild or mild to moderate Alzheimer's disease.
Further information about the CTW is available on: http://www.alzheimer-europe.org/Research/Clinical-Trials-Watch
